SUMMARY This paper announces the availability of the first international standard for anti-double-stranded DNA (anti-dsDNA 
The Netherlands. *This article is written on behalf of the Intcrnational Union of Immunological Societies standardisation committee on anti-dsDNA.
Union of Immunological Societies nominated for this purpose a subcommittee on anti-dsDNA. The chairman of this committee, T E W Feltkamp, received support from many workers all over the world (see 'Acknowledgments'). The nucleus of the committee, i.e., the authors of the present paper and E J Holborow and G D Johnson, agreed that the committee's task was to develop a reference standard serum which was available in a large quantity and contained anti-dsDNA activity, was stable when stored in freeze dried ampoules, and was suitable for use in at least the Farr assay and the immunofluorescence technique. These two techniques had performed consistently well in a comparative study organised by the years. An approximate upper 95% confidence limit for this rate is 3-5% per year. 13 These figures indicate an acceptable level of long term stability for Wo/80 when stored at -20°C or below. For periods of shipment the data indicate a predicted loss of 3-3% activity a month at 370C and 1*1% activity a month at 200C. These losses also appear to be acceptable.
Tests on the stability of the reconstituted content of Wo/80 when stored at -200C also showed reasonable stability under these conditions (Table 3) .
COLLABORATIVE STUDY
From the members of the subcommittee on standardisation of anti-dsDNA eight (see 'Acknowledgments') were selected for their experience in anti-dsDNA testing and willingness to cooperate in a study to see whether the serum Wo/80 could serve as a standard. The laboratories of these members The eight laboratories were asked to test the ampoules A, B, and Wo/80 on four separate dates with the immunofluorescence technique and the Farr assay according to fixed protocols. The tests had to be performed within six weeks.
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FARR ASSAY
The dilution curves from each of the assays were plotted and examined visually for linearity and parallelism. As no replication was carried out in the individual assays the linearity and parallelism of the dilution curves could not be tested statistically. Within assays coefficients of variation were therefore not determined. It was clear from the graphs that preparation A had no detectable activity in this assay method, and the results for this material were not considered further. For preparation B several data points fell outside the linear part of the dilution curve, and these points also were excluded. In a small proportion of assays no valid comparison seemed possible, and these assays were therefore discarded. The remaining data were included in a parallel line assay analysis according to Finney,'5 in which straight parallel lines were fitted for each assay, and, from these, potency ratios of the preparations versus Wo/80 were calculated. Fig. 1 shows the distribution of the potency ratios of B versus Wo/80 from the individual assays; these ranged from 0-241 to 0458. (A potency ratio R means that preparation B was estimated to be R times as potent as Wo/80.) Table 6 summarises these results and shows the geometric means and coefficients of variation within each laboratory. The laboratory means ranged from 0-260 to 0-365. One way analysis of variance among these means showed that the variation between laboratories was statistically significant (F6.19=4.30, p<0-01) when compared with the variation within laboratories. The overall geometric mean potency ratio was 0313 with a 95% confidence interval of 0-282-0348.
IMMUNOFLUORESCENCE TECHNIQUE
The results were calculated as the ratios of the titres of B versus Wo/80 at which the first position response (+) was recorded. Fig. 1 (lower panel) shows the distribution of potency ratios of B versus Wo/80, which ranged from 0a 125 to 0-5. Most of the potency ratios were either 0-25 or 05, the bimodality of the distribution reflecting the fact that the potencies were calculated as the ratios of titres. 
